Clinical Trial Update: Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE) [Phase 2]

View source ↗

Summary

Phase 2 trial updates on repeat intravitreal injections of Foselutoclax (UBX1325) for diabetic macular edema, reporting efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• Foselutoclax (UBX1325) (foselutoclax)

Snippet

Sponsor: Unity Biotechnology, Inc. | Conditions: Diabetic Macular Edema, Retinal Disease | Phase 2 | Status: COMPLETED | Results posted: 2025-08-05